Stock Events

Abeona Therapeutics 

$5.6
61
+$0.04+0.72% Wednesday 17:43

Statistics

Day High
5.6
Day Low
5.49
52W High
8.8
52W Low
2.35
Volume
302
Avg. Volume
1,007
Mkt Cap
15.54B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

11
NOV
Earnings
 

Earnings

11NovExpected
Q4 2022
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-1.16
-0.27
0.63
1.52
Expected EPS
-0.375
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0H7R.LSE. It's not an investment recommendation.
Alphabet
73232
GOOGL
Apple
63973
AAPL
Microsoft
59623
MSFT
Amazon
55040
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap29.83B
Biogen focuses on developing therapies for neurological and neurodegenerative diseases, directly competing with Abeona's gene therapy approach for similar disorders.
Pfizer
PFE
Mkt Cap164.39B
Pfizer has a broad portfolio including gene therapies targeting rare diseases, overlapping with Abeona's focus areas.
Sangamo Therapeutics
SGMO
Mkt Cap176.57M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, competing in the same space as Abeona for genetic disorders.
Biomarin Pharmaceutical
BMRN
Mkt Cap17.36B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for rare diseases, directly competing with Abeona's rare disease focus.
Bluebird bio
BLUE
Mkt Cap108.22M
bluebird bio focuses on gene therapies for genetic diseases and cancer, competing in the gene therapy space with Abeona.
Ultragenyx Pharmaceutical
RARE
Mkt Cap5.23B
Ultragenyx Pharmaceutical targets rare and ultra-rare diseases with its drug development, similar to Abeona's focus.
Sarepta Therapeutics
SRPT
Mkt Cap12.95B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics and gene therapy for rare diseases, competing with Abeona's gene therapy approach.
Vertex Pharmaceuticals
VRTX
Mkt Cap127.99B
Vertex Pharmaceuticals engages in developing therapies for treating cystic fibrosis and other serious diseases, competing in the rare disease market with Abeona.
Novo Nordisk
NVO
Mkt Cap620.4B
Novo Nordisk focuses on a broad range of treatments including for rare diseases, potentially competing with Abeona in the gene therapy and rare disease market.

About

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
Show more...
CEO
Dr. Vishwas Seshadri M.B.A., Ph.D.
Employees
84
Country
US
ISIN
US00289Y2063

Listings

XNAS
US
ABEO
LSE
GB
0H7R.LSE
F
DE
PCJ.F